Michael Flemmens brings over 20 years of experience as a research scientist in technical support and product development. Prior to SōRSE, he served as Director of Corporate Technology Development for Secant Group, LLC. Michael has worked on a patented new cancer treatment, had a Type IV Drug Master File approved by the FDA, and received JECFA approval for a new food ingredient. He has also designed the build-out of seven novel manufacturing lines and has held multiple government contracts for novel security products. Michael earned a B.S. in Chemistry from Towson University.